Table 4 Proteinuria reduction and treatment response in patients with IgA nephropathy/diabetic nephropathy treated with Acthar gel
From: Acthar gel in the treatment of nephrotic syndrome: a multicenter retrospective case series
Patient | Previous IST/CT | Concurrent medications | Serum albumin | SCr | Proteinuria | Treatment response |
|---|---|---|---|---|---|---|
Pre-Acthar | Pre-Acthar | Pre-Acthar | ||||
Post-Acthar (g/dL) | Post-Acthar % change (mg/dL) | Post-Acthar % change (mg/d) | ||||
IgAN | ||||||
1 | None | ARB, ACEI | 3.9 | 2.8 | 4000 | Early termination |
NA | NA | NA | ||||
NA | NA | |||||
2 | None | ARB, ACEI | 3.9 | 1.4 | 2674 | Clinical response |
NA | 1.5 | 1700 | ||||
7.1 | −36.4 | |||||
3 | None | ARB | 4.0 | 1.3 | 2439 | No response |
3.6 | 1.3 | 2360 | ||||
0 | −3.2 | |||||
4 | None | ACEI | 3.0 | 1.0 | 10000 | Early termination (Partial remission) |
4.0 | 1.0 | 800a | ||||
0 | −92.0 | |||||
5 | Prednisone, cyclophosphamide, azathioprine | ARB | NA | 1.3 | 2230 | Partial remission |
4.2 | 1.3 | 815 | ||||
0 | −63.5 | |||||
DN | ||||||
1 | None | ACEI | 2.0 | 1.9 | 25000 | No response |
2.0 | 4.9 | 23000 | ||||
157.9 | −8.0 | |||||
2 | None | ARB, ACEI | 3.3 | 3.4 | 14000 | Early termination |
3.3 | 4.4 | 11600a | ||||
29.4 | −17.1 | |||||
3 | None | ACEI | 3.1 | 4.8 | 17570 | No response |
2.8 | 5.7 | 18886 | ||||
18.8 | 7.5 | |||||
4 | None | ACEI | 3.4 | 2.5 | 11000 | Clinical response |
3.5 | 2.5 | 6895 | ||||
0 | −37.3 |